Dr Klein has had a direct role in the design, conduct, analysis and/or publication of several hundred clinical trials in a wide range of therapeutic areas. He has been involved in drug and device studies in more than thirty countries and has participated in numerous meetings with advisory panels and regulatory agencies in North America and Europe.

In addition to extensive consulting with multinational pharma and established and emerging biotech companies, he has advised charitable health care foundations as well as government agencies including the NIH and the National Health Service in the UK.

For VC and other investors Dr Klein has evaluated many acquisition and investment opportunities in biotech companies. Based on careful review of publicly available information, from time to time he has determined that a highly-touted product in Phase III, or under consideration for FDA approval, is unlikely to succeed. On such occasions he has recommended that his client sell short. To date he has a perfect record with such advice.



  • irritable bowel syndrome (IBS)
  • ulcerative colitis
  • Crohn’s disease
  • functional dyspepsia
  • GERD
  • viral hepatitis
  • pancreatitis
  • exocrine pancreatic insufficiency
  • short bowel syndrome

Neurology and Psychiatry


  • migraine
  • depression
  • bipolar disorder
  • epilepsy
  • acute pain
  • neuropathic pain
  • chronic pain
  • sexual dysfunction
  • Parkinson’s disease
  • schizophrenia
  • neuromuscular blocking drugs

Other Therapeutic Areas


  • diabetes
  • virology
  • oncology
  • cardiology
  • anesthesiology
  • sleep medicine
  • parasitology
  • aesthetics